Showing 61 - 80 results of 13,826 for search '(( significant amount decrease ) OR ( significantly reported case ))', query time: 0.57s Refine Results
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72
  13. 73
  14. 74

    DataSheet_2_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.pdf by Xian Chen (107385)

    Published 2022
    “…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
  15. 75

    DataSheet_3_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.csv by Xian Chen (107385)

    Published 2022
    “…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
  16. 76

    DataSheet_1_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.pdf by Xian Chen (107385)

    Published 2022
    “…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
  17. 77
  18. 78
  19. 79
  20. 80